The insufficient nitrate response: patients' characterization and response to beta and calcium blockade

S Silber1, A C Vogler, F Spiegelsberger

  • 1Medizinische Klinik Innenstadt, Universität München, F.R.G.

European Heart Journal
|January 1, 1988
PubMed

Insights

Isosorbide dinitrate (ISDN) effectively reduces left ventricular volumes during exercise in patients with good anti-ischaemic response. Objective monitoring of ISDN therapy is crucial for optimal treatment of exercise-dependent ischemia.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Limited data exists on nitrate-induced changes in left ventricular volumes related to anti-ischaemic response.
  • Isosorbide dinitrate (ISDN) is used for angina, but its effect on ventricular volumes and exercise response needs clarification.

Purpose of the Study:

  • To assess the relationship between electrocardiographically defined nitrate response and changes in left ventricular volumes at rest and during exercise.
  • To evaluate the effectiveness of additional beta-blockers or calcium channel blockers in patients with insufficient nitrate response.

Main Methods:

  • Radionuclide ventriculography was used to measure end-diastolic volumes in 63 patients with exercise-dependent ischaemia.
  • Patients were classified based on ST-segment depression reduction following ISDN administration.
  • Effects of verapamil and propranolol were assessed in a subset of patients.

Main Results:

  • Good responders showed a greater ISDN-induced decrease in end-diastolic volume at rest (-25%) compared to insufficient responders (-17%).
  • During exercise, ISDN significantly reduced end-diastolic volume in good responders (-19%) but not in insufficient responders.
  • Verapamil and propranolol offered equivalent benefits, with some patients requiring combination therapy for optimal anti-ischaemic effect.

Conclusions:

  • Preload reduction by ISDN plays a significant role in its anti-ischaemic effects for exercise-dependent ischaemia.
  • Objective monitoring of nitrate therapy, including exercise and Holter ECG, is essential for optimizing treatment outcomes.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...